These data suggest that enzymatic inhibition of MLL1 and KMT2D/MLL4, when combined with PI3K inhibition, is a promising therapeutic modality to induce cell death and produce a durable therapeutic response in PI3K-activated cancers. Here, KMT2A is linked to cancer.